TG THERAPEUTICS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
TG THERAPEUTICS, INC. (TGTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $107.74 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-27
- TG THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $107.74M, a 307.02% increase from fiscal 2024.
- TG THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $26.47M, a 94.88% increase from fiscal 2023.
- TG THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $13.58M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $107.74M 10-K · filed 2026-02-27 |
| 2024-12-31 | $26.47M 10-K · filed 2026-02-27 |
| 2023-12-31 | $13.58M 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |